Search Results - "Picozzi, Vincent J."

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors by Starodub, Alexander N, Ocean, Allyson J, Shah, Manish A, Guarino, Michael J, Picozzi, Jr, Vincent J, Vahdat, Linda T, Thomas, Sajeve S, Govindan, Serengulam V, Maliakal, Pius P, Wegener, William A, Hamburger, Steven A, Sharkey, Robert M, Goldenberg, David M

“…Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2, a surface glycoprotein expressed on many epithelial tumors, for delivery…”
Get full text

Pancreas Cancer‐Associated Weight Loss by Hendifar, Andrew E., Petzel, Maria Q.B., Zimmers, Teresa A., Denlinger, Crystal S., Matrisian, Lynn M., Picozzi, Vincent J., Rahib, Lola, Hendifar, Andrew, Tuli, Richard, Wolpin, Brian, Hidalgo, Manuel, Ryan, David, Hingorani, Sunil, Chiorean, Elena Gabriela, Coveler, Andrew, O'Reilly, Eileen, Balachandran, Vinod, Simeone, Diane, Lowy, Andrew, Fanta, Paul, Kurzrock, Razelle, Reid, Tony, Ko, Andrew, Collisson, Eric, Tempero, Margaret, Kindler, Hedy, George, Thomas, Trevino, Jose, Vonderheide, Robert, Beatty, Gregory, Picozzi, Vincent, Mandelson, Margaret, Wang‐Gillam, Andrea, Hawkins, William, Fleshman, Julie, Hidalgo, Manuel, Hingorani, Sunil, Maitra, Anirban, Manax, Victoria, Matrisian, Lynn, Picozzi, Vincent, Simeone, Diane

“…Unintentional weight loss in patients with pancreatic cancer is highly prevalent and contributes to low therapeutic tolerance, reduced quality of life, and…”
Get full text

Sustained Carbohydrate Antigen 19‐9 Response to Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer Predicts Progression and Survival by Rose, J. Bart, Edwards, Alicia M., Rocha, Flavio G., Clark, Carolyn, Alseidi, Adnan A., Biehl, Thomas R., Lin, Bruce S., Picozzi, Vincent J., Helton, W. Scott

“…Background As neoadjuvant therapy of borderline resectable pancreatic cancer (BRPC) is becoming more widely used, better indicators of progression are needed…”
Get full text

Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Statement by Abrams, Ross A., Lowy, Andrew M., O’Reilly, Eileen M., Wolff, Robert A., Picozzi, Vincent J., Pisters, Peter W. T.

Get full text

A randomized phase II study of SM‐88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond by Noel, Marcus S., Kim, Semmie, Hartley, Marion L., Wong, Steve, Picozzi, Vincent J., Staszewski, Harry, Kim, Dae Won, Van Tornout, Jan M., Philip, Philip Agop, Chung, Vincent, Ocean, Allyson J., Wang‐Gillam, Andrea

“…Background This trial explores SM‐88 used with methoxsalen, phenytoin, and sirolimus (MPS) in pretreated metastatic pancreatic ductal adenocarcinoma (mPDAC)…”
Get full text

Treatment of advanced pancreatic cancer: When will the third time be a charm? by Picozzi, Vincent J.

“…Third‐line treatment of pancreatic cancer remains a major challenge for oncologists. What is its current status?…”
Get full text

Afferent limb syndrome and delayed GI problems after pancreaticoduodenectomy for pancreatic cancer: single-center, 14-year experience by Pannala, Rahul, MD, Brandabur, John J., MD, Gan, Seng-Ian, MD, Gluck, Michael, MD, Irani, Shayan, MD, Patterson, David J., MD, Ross, Andrew S., MD, Dorer, Russell, MD, Traverso, L. William, MD, Picozzi, Vincent J., MD, Kozarek, Richard A., MD

“…Background There are limited data on the incidence of afferent limb syndrome and other delayed GI problems in pancreatic cancer (PaC) patients, especially…”
Get full text

Localized pancreatic cancer with positive peritoneal cytology as a sole manifestation of metastatic disease: a single institution experience by Oh, Stephen Y., MBBS, BSc, Edwards, Alicia, MBA, Mandelson, Margaret T., PhD, Hahn, Hejin, MD, Alseidi, Adnan, MD, Biehl, Thomas, MD, Kozarek, Richard A., MD, Rocha, Flavio G., MD, Helton, Scott, MD, Picozzi, Vincent J., MD

“…Abstract Background Pancreatic cancer patients with positive peritoneal cytology (PPC) as a sole metastatic site are poorly characterized. Whether they behave…”
Get full text

Pancreatic cancer: new approaches to drug therapy by Picozzi, Vincent J

“…Outcomes in pancreatic ductal adenocarcinoma (PDAC) remain poor due to a variety of biological, clinical, and societal factors. However, in recent years, PDAC…”
Get full text

Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma by Picozzi, Vincent J, Kozarek, Richard A, Traverso, L.William

“…Patients with cancer who undergo pancreaticoduodenectomy (PD) followed by radiation and 5-fluorouracil (5-FU) therapy have experienced median overall survival…”
Get full text

Anemia in the elderly: a public health crisis in hematology by Guralnik, Jack M, Ershler, William B, Schrier, Stanley L, Picozzi, Vincent J

“…Over 3 million people in the United States aged 65 years and older are anemic. This condition is associated with significant functional impairment and,…”
Get full text

Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma by Forero, Andres, Weiden, Paul L., Vose, Julie M., Knox, Susan J., LoBuglio, Albert F., Hankins, Jordan, Goris, Michael L., Picozzi, Vincent J., Axworthy, Don B., Breitz, Hazel B., Sims, Robert B., Ghalie, Richard G., Shen, Sui, Meredith, Ruby F.

“…Pretargeted radioimmunotherapy (PRIT) has the potential to increase the dose of radionuclide delivered to tumors while limiting radiation to normal tissues…”
Get full text

Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative by Pishvaian, Michael J, Bender, Robert J, Halverson, David, Rahib, Lola, Hendifar, Andrew E, Mikhail, Sameh, Chung, Vincent, Picozzi, Vincent J, Sohal, Davendra, Blais, Edik M, Mason, Kimberly, Lyons, Emily E, Matrisian, Lynn M, Brody, Jonathan R, Madhavan, Subha, Petricoin, 3rd, Emanuel F

“…To broaden access to and implementation of precision medicine in the care of patients with pancreatic cancer, the Know Your Tumor (KYT) program was initiated…”
Get full text

Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study) by Le, Dung T, Picozzi, Vincent J, Ko, Andrew H, Wainberg, Zev A, Kindler, Hedy, Wang-Gillam, Andrea, Oberstein, Paul, Morse, Michael A, Zeh, 3rd, Herbert J, Weekes, Colin, Reid, Tony, Borazanci, Erkut, Crocenzi, Todd, LoConte, Noelle K, Musher, Benjamin, Laheru, Dan, Murphy, Aimee, Whiting, Chan, Nair, Nitya, Enstrom, Amanda, Ferber, Sandy, Brockstedt, Dirk G, Jaffee, Elizabeth M

“…Limited options exist for patients with advanced pancreatic cancer progressing after 1 or more lines of therapy. A phase II study in patients with previously…”
Get full text

Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics by Ocean, Allyson J., Starodub, Alexander N., Bardia, Aditya, Vahdat, Linda T., Isakoff, Steven J., Guarino, Michael, Messersmith, Wells A., Picozzi, Vincent J., Mayer, Ingrid A., Wegener, William A., Maliakal, Pius, Govindan, Serengulam V., Sharkey, Robert M., Goldenberg, David M.

“…BACKGROUND Sacituzumab govitecan (IMMU‐132), an antitrophoblastic cell‐surface antigen (anti‐Trop‐2) humanized antibody‐SN‐38 conjugate, had encouraging…”
Get full text

Alternating Gemcitabine/Nab-Paclitaxel (GA) and 5-FU/Leucovorin/Irinotecan (FOLFIRI) as First-Line Treatment for De Novo Metastatic Pancreatic Cancer (MPC): Safety and Effect by Schroeder, Brett A, Mandelson, Margaret T, Picozzi, Vincent J

“…Both gemcitabine- and 5-fluorouracil (5-FU)-based chemotherapy regimens have demonstrated efficacy in metastatic pancreatic cancer (MPC). Alternating these…”
Get full text

A Phase II, Single‐Arm, Open‐Label, Bayesian Adaptive Efficacy and Safety Study of PBI‐05204 in Patients with Stage IV Metastatic Pancreatic Adenocarcinoma by Roth, Marc T., Cardin, Dana Backlund, Borazanci, Erkut Hasan, Steinbach, Margaux, Picozzi, Vincent J., Rosemury, Alexander, Wadlow, Raymond Couric, Newman, Robert A., Berlin, Jordan

“…Lessons Learned This trial evaluating a novel plant extract, PBI‐05204, did not meet its primary endpoint of overall survival but did show signals of efficacy…”
Get full text

Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma by Nukui, Yuji, Picozzi, Vincent J, Traverso, L.William

“…Background: Based on a 2-year survival of 43%, the Gastrointestinal Tumor Study Group (GITSG) recommended adjuvant 5-FU-based chemoradiation for resected…”
Get full text

Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective by Picozzi, Vincent J., Oh, Stephen Y., Edwards, Alicia, Mandelson, Margaret T., Dorer, Russell, Rocha, Flavio G., Alseidi, Adnan, Biehl, Thomas, Traverso, L. William, Helton, William S., Kozarek, Richard A.

“…Background Successful surgical resection combined with effective perioperative therapy is essential for maximizing long-term survival for pancreatic…”
Get full text

Multi-omic molecular comparison of primary versus metastatic pancreatic tumours by Brar, Gagandeep, Blais, Edik M., Joseph Bender, R., Brody, Jonathan R., Sohal, Davendra, Madhavan, Subha, Picozzi, Vincent J., Hendifar, Andrew E., Chung, Vincent M., Halverson, David, Mikhail, Sameh, Matrisian, Lynn M., Rahib, Lola, Petricoin, Emanuel, Pishvaian, Michael J.

“…Background Molecular profiling is increasingly used to match patients with metastatic cancer to targeted therapies, but obtaining a high-quality biopsy…”
Get full text